Final Overview of MDR HIV Treatment Landscape

EP: 1.Incidence and Prevalence of MDR HIV

EP: 2.Resistance Mechanisms Leading to MDR HIV

EP: 3.Economic and Social Burdens Associated with MDR HIV

EP: 4.Social Determinants of Health Impacting Patients Diagnosed with MDR HIV

EP: 5.Pharmacotherapeutic Treatment Options for Treating MDR HIV

EP: 6.MDR HIV Treatment Approaches and Considerations for Therapeutic Adjustments

EP: 7.Patient and Payer Considerations for Medication Regimen Adherence In MDR HIV Treatment Pathway

EP: 8.Considerations with Non-Adherence to Standard Background MDR HIV Therapy

EP: 9.Payers and Clinicians Impacted by CD4 Recovery

EP: 10.Medication Burden and Stigma Impacting Adherence Rates in Patients With MDR HIV

EP: 11.Cost of Care Implications for Treated Versus Non-Treated MDR HIV

EP: 12.Optimal Treatment of MDR HIV Impacting Population Health

Now Viewing

EP: 13.Final Overview of MDR HIV Treatment Landscape

Ryan Haumschild, PharmD, MS, MBA: Thanks to all of you for this rich and informative discussion. Before we conclude, I’d like to get final thoughts from each of you. Dr Sension, what are your final thoughts for our viewers after this discussion?

Michael Sension, MD: Multidrug resistance is a very interesting discussion. Each person who’s facing multidrug-resistant virus in their body is different. Each person has to have a customized approach to successful management. There’s no treatment algorithm or formula for treating multidrug resistance, but it truly is the art of medicine interacting with real human life patient dynamics that will successfully lead to a positive outcome.

Ryan Haumschild, PharmD, MS, MBA: I love the individual view of treatment. You’ve definitely given us a lot to think about with that shared decision-making framework. Dr Lopes, [what are] your final thoughts for our audience?

Maria Lopes, MD, MS: It’s an exciting time as we have more treatment options for this very small population. We started with less than 1%, and now we have 3 treatment options. There’s still the backbone issue, so it’s incumbent to focus on shared decision-making but also support and adherence. It’s not about 1 drug, so how can we improve the value of these treatments and get successful outcomes?

Ryan Haumschild, PharmD, MS, MBA: [There are] lots of innovations in therapy, but [there’s] still more work to be done. Mr Driffin, I’ll give you the final thoughts.

Daniel Driffin, BS, MPH: The conversation must be centered on social determinants of health. We have to have those ongoing conversations to ensure that solutions are being provided. Solutions include support systems, housing, employment, and insurance access, but also to ensure that individuals living with HIV have a valuable role in being the healthiest they can be with their medical providers.

Ryan Haumschild, PharmD, MS, MBA: Thank you to my expert panel and our viewing audience. We hope you found this AJMC® Peer Exchange to be useful and informative.

Transcript edited for clarity.